CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension
by
, , , , , and
Michał Tomaszewski
1
,
Paulina Małkowska
2,3,
Olga Sierawska
2,3,
Rafał Hrynkiewicz
3
,
Ewa Mroczek
4,
Szymon Darocha
5,
Anna Hymos
6,
Piotr Błaszczak
7,
Ewelina Grywalska
6 and
Paulina Niedźwiedzka-Rystwej
3,*
1
Department of Cardiology, Medical University of Lublin, 20-954 Lublin, Poland
2
Doctoral School, University of Szczecin, 71-412 Szczecin, Poland
3
Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland
4
Department of Cardiology, Institute of Heart Diseases, Jan Mikulicz-Radecki University Teaching Hospital, 51-124 Wroclaw, Poland
5
Department of Pulmonary Hypertension, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, 05-400 Otwock, Poland
6
Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland
7
Department of Cardiology, Cardinal Wyszynski Hospital, 20-718 Lublin, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2022, 23(24), 15910; https://doi.org/10.3390/ijms232415910
Submission received: 8 October 2022
/
Revised: 6 December 2022
/
Accepted: 7 December 2022
/
Published: 14 December 2022
(This article belongs to the Special Issue Pathophysiology and Treatment of Pulmonary Arterial Hypertension)
Abstract
:Pulmonary arterial hypertension (PAH) is an increasingly frequently diagnosed disease, the molecular mechanisms of which have not been thoroughly investigated. The aim of our study was to investigate subpopulations of lymphocytes to better understand their role in the molecular pathomechanisms of various types of PAH and to find a suitable biomarker that could be useful in the differential diagnosis of PAH. Using flow cytometry, we measured the frequencies of lymphocyte subpopulations CD4+CTLA-4+, CD8+ CTLA-4+ and CD19+ CTLA-4+ in patients with different types of PAH, namely pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH), pulmonary arterial hypertension associated with connective tissue disorders (CTD-PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (iPAH), and in an age- and sex-matched control group in relation to selected clinical parameters. Patients in the iPAH group had the significantly highest percentage of CD4+CTLA-4+ T lymphocytes among all PAH groups, as compared to those in the control group (p < 0.001), patients with CTEPH (p < 0.001), CTD-PAH (p < 0.001) and CHD-PAH (p < 0.01). In iPAH patients, the percentages of CD4+CTLA-4+ T cells correlated strongly positively with the severity of heart failure New York Heart Association (NYHA) Functional Classification (r = 0.7077, p < 0.001). Moreover, the percentage of B CD19+CTLA-4+ cells strongly positively correlated with the concentration of NT-proBNP (r = 0.8498, p < 0.001). We have shown that statistically significantly higher percentages of CD4+CTLA-4+ (p ≤ 0.01) and CD8+ CTLA-4+ (p ≤ 0.001) T cells, measured at the time of iPAH diagnosis, were found in patients who died within 5 years of the diagnosis, which allows us to consider both of the above lymphocyte subpopulations as a negative prognostic/predictive factor in iPAH. CTLA-4 may be a promising biomarker of noninvasive detection of iPAH, but its role in planning the treatment strategy of PAH remains unclear. Further studies on T and B lymphocyte subsets are needed in different types of PAH to ascertain the relationships that exist between them and the disease.
1. Introduction
Pulmonary arterial hypertension (PAH) is a severe clinical condition characterized by enhanced pulmonary vascular resistance (PVR), leading to increased pulmonary artery pressure (PAP)and the remodeling of the pulmonary arteries [1]. If left untreated, it leads to deterioration of right ventricular function, multiorgan failure and death. Invasive hemodynamic evaluation with right heart catheterization is the gold standard to establish the diagnosis of PAH. According to a recent update, pulmonary arterial hypertension (PAH) is diagnosed when the mean pulmonary artery pressure (mPAP) is ≥20 mm Hg and the normal pulmonary capillary wedge pressure (PCWP) is ≤15 mm Hg [2].
Consistent with the European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines, there are five groups of pulmonary hypertension (PH), according to clinical and pathophysiological criteria: group 1 refers to idiopathic pulmonary arterial hypertension (iPAH), as well as drug-induced PAH, connective tissue disease-related PAH and all heritable forms of PAH; group 2 includes the PH secondary to left-sided heart failure; group 3 includes PH due to the chronic lung disease and/or hypoxia; group 4 is called chronic thromboembolic pulmonary hypertension (CTEPH); group 5 consists of PAH due to uncertain multifactorial mechanisms [3,4].
Targeted medical therapy or interventional treatment can be offered to patients diagnosed with PAH and CTEPH, respectively. The prognosis of PAH varies broadly and depends mostly on the etiology of PAH, but is also based on hemodynamic, biochemical and functional parameters that indicate the severity of right ventricular failure, as well as on response to specific treatment. Risk stratification seems to be crucial for identifying patients at high risk and for optimizing therapeutic management. Thus, biomarkers and molecules may specifically indicate the disease and provide information about the disease stage and treatment response in a relatively easily accessible and noninvasive way.
CTLA-4 (cytotoxic t cell antigen 4) (CD152) molecules belong to the type I membrane receptor family and play an important role in signaling between immune cells [5]. CTLA-4 is mainly localized on the surface of activated CD4+ T cells and regulatory T cells (Treg), as well as on B19+ cells and dendritic cells [5,6]. The ligands of this receptor are CD80 and CD86 molecules, which are mostly seen on antigen-presenting cells. The main function of CTLA-4 is inhibitory; it is a key element in the negative regulation of the immune response, and when combined with a specific ligand, it inhibits T lymphocytes [7]. Two types of mechanisms influence this. The first is an extracellular mechanism and involves affecting the ability of antigen presenting cells (APCs) to stimulate T cells. The second mechanism is intracellular and involves suppression of signals sent to T cells [8]. The reproducibility of CTLA-4 measurements were shown by Grywalska et al. [9,10].
The aim of the present study was to investigate lymphocyte subpopulations and better understand their role in the molecular pathomechanisms of different types of PAH, and to find a new biomarker that could be useful and widely used in the differential diagnosis of PAH.
2. Results
Cytometric analysis allowed us to determine the percentage of CD19+ B cells, CD4+ T cells and CD8+ T cells with CTLA-4 receptor expression (Figure 1).
Patients in the iPAH group had, by significant distance, the highest percentage of CD4+CTLA-4+ T lymphocytes among all PAH groups, as compared to those in the control group (p < 0.001), patients with CTEPH (p < 0.001), CTD-PAH (p < 0.001) and CHD-PAH (p < 0.01). Additionally, a higher percentage of CD4+CTLA4+ T lymphocytes was observed in CHD-PAH patients, as compared to CTD-PAH (p < 0.001) and CTEPH (p < 0.01) patients. The lowest percentage of CD4+CTLA4+ T lymphocytes was in the group of patients with CTD-PAH, which was statistically significant when compared to the control group (p < 0.01) (Table 1). The obtained relationships are presented in Figure 2.
Comparison of the percentage of CD8+CTLA4+ T lymphocytes in selected types of PAH and in the control group revealed a significantly higher percentage of these lymphocytes in the group of patients with iPAH than in the control group (p < 0.001). The obtained relationships are shown in Figure 3.
Comparison of the percentage of CD19+CTLA4+ B lymphocytes in selected types of PAH and in the control group revealed a significantly higher percentage of these lymphocytes in the iPAH group than in the CTD-PAH and CHD-PAH groups (p < 0.05). The resulting relationships are shown in Figure 4.
We have shown that statistically significantly higher percentages of CD4+CTLA-4+ (p ≤ 0.01, Figure 5) and CD8+ CTLA-4+ (p ≤ 0.001, Figure 6) T cells, measured at the time of IPAH diagnosis, were found in patients who died within 5 years of the diagnosis, which allows us to consider both of the above lymphocyte subpopulations as a negative prognostic/predictive factor in iPAH.
The percentages of CD4+CTLA-4+ T cells correlated strongly positively with the severity of heart failure New York Heart Association (NYHA) Functional Classification (Spearman’s rank correlation r = 0.7077, p < 0.001, Figure 7).
Moreover, the percentage of B CD19+CTLA-4+ cells strongly positively correlated with the concentration of NT-proBNP (r = 0.8498, p < 0.001, Figure 8).
3. Discussion
In this study, we analyzed lymphocyte subpopulations—CD4+, CD8+, CD19+—and surface antigen CTLA-4 in patients with different types of PAH: CHD-PAH, CTD-PAH, CTEPH and iPAH. Accordingly, CD4+, CD8+ and CD19+ levels were studied mostly in patients with iPAH. There are few data on patients with CHD-PAH, CTD-PAH and CTEPH so our study also focused on other types of PAH. CHD-PAH occurs in 5–10% of congenital heart disease (CHD) patients, mostly woman [11]. CTD-PAH is most common in patients with systemic scleroderma and its development contributes to poor disease prognosis and an increased risk of death [12]. CTEPH is a relatively rare type of PAH, possibly due to the great difficulty in diagnosis [13].
We focused on CTLA-4, which is a receptor on the surface of lymphocytes. This was because CTLA-4 controls T cell responses, alongside manipulation of CTLA-4, has become a cornerstone in the development of therapies for autoimmune diseases and cancer [14]. In general, CTLA-4 is a widely studied antigen for the treatment of malignancies; however, the close association of CTLA-4 blockade with the development of immune toxicity is problematic. The use of anti-CTLA4 blocking antibody has the effect of increasing Th17 cells in patients with metastatic melanoma, which enhances immune toxicity [15].
In our study, we observed a twofold increase in CD4+CTLA-4+ in patients with iPAH, but a decrease in patients with CTD-PAH and CTEPH. In CD4+ studies without CTLA-4, an increase in CD4+ T cells was reported in patients with PAH [16,17]. CD4+ T lymphocytes aggravate PAH progression, increase inflammation and exert autoimmune effects through the secretion of cytokines IL-2, IL-4, IL-6, IL-13, IL-21, TNF-α and IFN-γ by CD4+ T cells [18]. It was reported that CTLA-4 expression levels were elevated on activated Th cells in iPAH [19]. Moreover, an increased percentage of cTfh-17 cells in the CD4+ population was observed in patients with iPAH [20]. A study by Maston et al. [21] in mouse models showed that CD4+ cells have a role in the development of hypoxia induced by PAH. Additionally, in normoxic and CH mice, Th17 was present in the cells, along with increased levels of pro-inflammatory IL-6. This suggests that T cells have a role in PAH induction [21]. In CD4+ T cells cultured in the presence of monocyte-derived DCs (MoDCs) from patients with PAH, reduced expression of IL-4 (Th 2 response) and higher levels of IL-17 (Th17 response) and increased activation and proliferation of CD4+ T cells were observed, as compared with CD4+ T cells cultured with MoDCs from control patients [22]. In current literature, an increase in Treg levels in iPAH patients has been reported [23,24]. Sada et al. [25] concluded in a study of Treg cells in iPAH patients that CTLA-4 expression levels in the immunosuppressive CD4CD45RA+-FoxP3high aTregs (aTregs) and CD4CD45RA+-FoxP3low non-Tregs (non-Tregs) subgroups were higher than those in control patients; however, the level of aTregs subgroup in iPAH patients did not change when compared with healthy patients, and the level of non-Tregs subgroup was higher than in healthy patients [25]. In addition, Tm levels were increased in iPAH patients [24]. Our data show differences in CD4+CTLA-4+ levels in patients with iPAH versus CTD-PAH and CTEPH. This information sheds new light on previous studies. Because decreased CD4+CTLA-4+ levels in patients with CTD-PAH and CTEPH may correlate with the development of immune toxicity and, therefore, a severe disease course, we suggest further studies of the CD4+CTLA+ group as divided into CD4+ Th, Treg and Tm cells. Such work may provide the information needed to understand the mechanisms involved in CD4+ in patients with PAH.
In this study, we observed an increase in CD8+CTLA4+ T lymphocytes. We thus conclude that CD8+ T lymphocytes aggravate PAH progression, increase inflammation and exert autoimmune effects, albeit through strong cytolytic activity [26]. However, in a study by Hautefort et al. [22], no changes in CD8+ counts were found in patients with PAH. Still, an increase in CD8+ levels in patients with iPAH was reported [16,27] and Ulrich et al. [23] reported a decrease in CD8+ levels. In contrast, the percentage of CD8+ T cells was much higher than other T cells, and it seems that the inflammatory infiltrate in PAH consisted mainly of CD8+ [17,28]. A role for Tc in autoimmunity in PAH has been suggested based on information gleaned from tumor studies [23].
An absence of changes in CD19+ B lymphocytes levels in patients with PAH had been reported [20,22]. In our study, however, we observed an increase in CD19+CTLA-4+ in patients with iPAH, and a decrease in patients with CHD-PAH and CTD-PAH. The elevated levels of CTLA-4 found on B lymphocytes is an interesting observation because, under conditions of body equilibrium, CTLA-4 is not locatable on B lymphocytes [29]. Since CTLA-4 can appear on the surface of B lymphocytes as a result of activation by T lymphocytes [30], the elevated levels of CD19+CTLA-4+ may be a response to enhanced levels of CD4+CTLA-4+ and CD8+CTLA-4+ [31].
Limitations of the Study
The limitation of the study is that it involves a small study group. The enrollment to the study was quite difficult because PAH is a rare disease and we only selected newly diagnosed PAH patients using quite strict inclusion criteria, such as no infection three months prior to the study, being without immunomodulatory treatment, no presence of allergy, etc. We only found 25 iPAH patients fulfilling the parameters. A larger study group may, therefore, provide more statistically significant correlations or differences between PAH patients and healthy controls.
4. Material and Methods
The study was conducted on 70 patients with PAH (50 women and 20 men). The diagnosis of PAH was based on ESC/ERS Guidelines [32]. The age of the patients was on average 57.74 ± 17.17 years (median: 60 years, minimum: 23 years, maximum: 81 years). Patients were classified by type of pulmonary arterial hypertension into chronic thromboembolic pulmonary hypertension (CTEPH) (10 patients, 7 women), PAH associated with congenital heart disease (CHD-PAH) (26 patients, 19 women), pulmonary arterial hypertension associated with systemic connective tissue disease (CTD-PAH) (9 patients, 9 women), and idiopathic pulmonary arterial hypertension (iPAH) (25 patients, 15 women). The heritable PAH patients were not included in this study. In patients with PAH, the WHO functional class of heart failure was established. The basic clinical and laboratory parameters characterizing patients with selected types of PAH and persons from the control group are decribed in Table 2. The basic hemodynamic parameters assessed during cardiac catheterization and echocardiography in patients with CHD-PAH, CTD-PAH, CTEPH and iPAHare delineated in Table 3.
The study was conducted in subjects who showed no signs of infection or allergy and did not have immunosuppressive treatment or a blood transfusion in the 3 months prior to the study.
The control group consisted of 20 subjects (12 women and 8 men) aged 58.1 ± 11.1 years (median: 56 years; minimum: 39 years; maximum: 77 years). Only subjects with no history of cardiovascular disease, no history of treatment with agents affecting the immune system, no history of infection, no history of autoimmune disease, no history of allergy and no history of blood transfusion were selected as volunteers.
The protocol of the conducted study received a positive opinion of the Bioethics Committee at the Medical University of Lublin (number KE-0254/309/2016). The material for the study was peripheral blood, which was collected from patients with pulmonary arterial hypertension and from the control group. Accordingly, 10 mL of blood was collected into tubes containing EDTA via an aspiration-vacuum system (Sarstedt, Germany). The collected blood was immediately processed to obtain plasma, to evaluate lymphocyte immunophenotypeand to isolate peripheral blood mononuclear cells (PBMCs).
4.1. Cytometric Analysis
Cytometric analysis was performed using CellQuest software (Becton Dickinson, Franklin Lakes, NJ, USA). The employment of a FACSCalibur flow cytometer (Becton Dickinson, USA) equipped with an argon laser (wavelength 488 nm) allowed for the reading of the following parameters: FSC, SSC, FL-1 (green fluorescence intensity), FL-2 (orange fluorescence intensity) and FL-3 (red fluorescence intensity). Herein, fluorescence intensity is dependent on antigen binding by monoclonal antibodies labeled with the appropriate fluorochromes.
Lymphocyte subpopulation and surface antigen analysis was performed with 20,000 cells counted from the lymphocyte gate (R1 region). The correct position of the gate was confirmed by using antibodies directed to CD45 and CD14 antigens. The result of the cytometric analysis was presented as the percentage of cells positively stained with the respective monoclonal antibodies.
To assess the presence of peripheral blood lymphocyte surface antigens, the appropriate monoclonal antibodies were separated into tubes at 20 µL. Subsequently, 50 µL of whole blood was added to each tube and the monoclonal antibodies were incubated with whole blood for 20 min at room temperature. Table 4 shows the monoclonal antibodies used for labeling and lists the fluorochromes to which they were conjugated.
4.2. Statistical Analysis
Descriptive characteristics of continuous variables were presented as: arithmetic mean, standard deviation (SD), minimum value, maximum value and median. Intergroup comparisons were performed using analysis of variance (ANOVA) with Duncan’s or Games–Howell post-hoc tests, depending on verification of the assumptions of analysis of variance, or the Kruskal–Wallis test with Dunn’s post-hoc test. Comparison of mean values of independent variables depended on meeting the criteria of normality of distributions and equality of variance was performed using Student’s t tests for independent samples.
5. Conclusions
Patients in the iPAH group had the significantly highest percentage of CD4+CTLA-4+ T lymphocytes among all PAH groups, as compared to those in the control group, patients with CTEPH, CTD-PAH and CHD-PAH.In iPAH patients, the percentages of CD4+CTLA-4+ T cells correlated strongly positively with the severity of heart failure New York Heart Association (NYHA) Functional Classification. Moreover, the percentage of B CD19+CTLA-4+ cells strongly positively correlated with the concentration of NT-proBNP. We have shown that statistically significantly higher percentages of CD4+CTLA-4+ and CD8+ CTLA-4+ T cells, measured at the time of iPAH diagnosis, were found in patients who died within 5 years of the diagnosis, which allows us to consider both of the above lymphocyte subpopulations as a negative prognostic/predictive factor in iPAH. CTLA-4 may be a promising biomarker of noninvasive detection of iPAH, but its role in planning the treatment strategy of PAH remains unclear. Further studies on T and B lymphocyte subsets are needed in different types of PAH to ascertain the relationships that exist between them and the disease.
Author Contributions
Conceptualization, M.T. and E.G.; methodology, M.T., O.S., P.M., R.H., E.M., S.D., A.H., E.G. and P.N.-R.; software, M.T., O.S., P.M., R.H., E.M., S.D., P.B., A.H., E.G. and P.N.-R.; validation, M.T., O.S., P.M., R.H., P.B., E.G. and P.N.-R.; formal analysis, M.T., O.S., P.M., R.H., P.B., A.H., E.G. and P.N.-R.; investigation, M.T., O.S., P.M., R.H., P.B., A.H., E.G. and P.N.-R.; resources, M.T., O.S., P.M., R.H., E.G. and P.N.-R.; data curation, M.T., O.S., P.M., R.H., E.M., S.D.,A.H., E.G. and P.N.-R.; writing—original draft preparation, M.T., O.S., P.M., E.M., S.D. and P.N.-R.; writing—review and editing, R.H. and E.G.; visualization, M.T., O.S., P.M., R.H., E.M., S.D., P.B., A.H., E.G. and P.N.-R.; supervision, M.T., E.G. and P.N.-R.; project administration, M.T., O.S., P.M., R.H., E.G. and P.N.-R.; funding acquisition, M.T., A.H. and E.G. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by the Medical University of Lublin, grant no. DS640, grant no. PBmb164 and grant no. DS376.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Lublin (KE-0254/309/2016, date of approval: 9 November 2016).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
Due to privacy and ethical concerns, the data that support the findings of this study are available on request from the First Author, (M.T.).
Conflicts of Interest
The authors declare no conflict of interest.
References
- Humbert, M.; Kovacs, G.; Hoeper, M.M.; Badagliacca, R.; Berger, R.M.; Brida, M.; Carlsen, J.; Coats, A.J.; Escribano-Subias, P.; Ferrari, P.; et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2022, 30, 2200879. [Google Scholar] [CrossRef]
- Zelt, J.G.; Sugarman, J.; Weatherald, J.; Partridge, A.C.; Liang, J.; Swiston, J.; Brunner, N.; Chandy, G.; Stewart, D.J.; Contreras-Dominguez, V.; et al. Mortality trends in pulmonary arterial hypertension in Canada: A temporal analysis of survival per ESC/ERS guideline era. Eur. Respir. J. 2021, 59, 2101552. [Google Scholar] [CrossRef]
- Ruaro, B.; Salton, F.; Baratella, E.; Confalonieri, P.; Geri, P.; Pozzan, R.; Torregiani, C.; Bulla, R.; Confalonieri, M.; Matucci-Cerinic, M.; et al. An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients. Diagnostics 2022, 12, 616. [Google Scholar] [CrossRef]
- Ruaro, B.; Baratella, E.; Caforio, G.; Confalonieri, P.; Wade, B.; Marrocchio, C.; Geri, P.; Pozzan, R.; Andrisano, A.G.; Cova, M.A.; et al. Chronic Thromboembolic Pulmonary Hypertension: An Update. Diagnostics 2022, 12, 235. [Google Scholar] [CrossRef]
- Tomaszewski, M.; Bębnowska, D.; Hrynkiewicz, R.; Dworzyński, J.; Niedźwiedzka-Rystwej, P.; Kopeć, G.; Grywalska, E. Role of the Immune System Elements in PulmonaryArterialHypertension. J. Clin. Med. 2021, 10, 3757. [Google Scholar] [CrossRef]
- Abramiuk, M.; Bębnowska, D.; Hrynkiewicz, R.; Niedźwiedzka-Rystwej, P.; Polak, G.; Kotarski, J.; Roliński, J.; Grywalska, E. CLTA-4 Expression Is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility. Cells 2021, 10, 487. [Google Scholar] [CrossRef]
- Pentcheva-Hoang, T.; Corse, E.; Allison, J.P. Negative regulators of T-cell activation: Potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol. Rev. 2009, 229, 67–87. [Google Scholar] [CrossRef]
- Kong, K.-F.; Fu, G.; Zhang, Y.; Yokosuka, T.; Casas, J.; Canonigo-Balancio, A.J.; Bécart, S.; Kim, G.; Yates, J.R.; Kronenberg, M.; et al. Protein kinase C-η controls CTLA-4–mediated regulatory T cell function. Nat. Immunol. 2014, 15, 465–472. [Google Scholar] [CrossRef] [Green Version]
- Grywalska, E.; Smarz-Widelska, I.; Mertowski, S.; Gosik, K.; Mielnik, M.; Podgajna, M.; Abramiuk, M.; Drop, B.; Roliński, J.; Załuska, W. CTLA-4 Expression Inversely Correlates with Kidney Function and Serum Immunoglobulin Concentration in Patients with Primary Glomerulonephritides. Arch. Immunol. Et Ther. Exp. 2019, 67, 335–349. [Google Scholar] [CrossRef] [Green Version]
- Grywalska, E.; Mielnik, M.; Podgajna, M.; Hymos, A.; Ludian, J.; Rolińska, A.; Gosik, K.; Kwaśniewski, W.; Sosnowska-Pasiarska, B.; Smok-Kalwat, J.; et al. Expression of CTLA-4 and CD86 Antigens and Epstein-Barr Virus Reactivation in Chronic Lymphocytic Leukemia—Any Link with Known Prognostic Factors? Cancers 2022, 14, 672. [Google Scholar] [CrossRef]
- Pascall, E.; Tulloh, R. Pulmonary hypertension in congenital heart disease. Future Cardiol. 2018, 14, 343–353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zanatta, E.; Polito, P.; Famoso, G.; Larosa, M.; De Zorzi, E.; Scarpieri, E.; Cozzi, F.; Doria, A. Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. Exp. Biol. Med. 2019, 244, 120–131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kazimierczyk, R.; Kamiński, K.A. Przewlekłe zakrzepowo-zatorowe nadciśnienie płucne—Diagnostyka i nowe możliwości terapii farmakologicznej w świetle wytycznych ESC/ERS 2015. Folia Cardiol. 2016, 11, 394–400. [Google Scholar] [CrossRef] [Green Version]
- Hou, T.Z.; Qureshi, O.S.; Wang, C.J.; Baker, J.; Young, S.P.; Walker, L.S.K.; Sansom, D.M. A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells. J. Immunol. 2015, 194, 2148–2159. [Google Scholar] [CrossRef] [Green Version]
- Von Euw, E.; Chodon, T.; Attar, N.; Jalil, J.; Koya, R.C.; Comin-Anduix, B.; Ribas, A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 2009, 7, 35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marsh, L.M.; Jandl, K.; Grünig, G.; Foris, V.; Bashir, M.; Ghanim, B.; Klepetko, W.; Olschewski, H.; Olschewski, A.; Kwapiszewska, G. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2018, 51, 1701214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Savai, R.; Pullamsetti, S.S.; Kolbe, J.; Bieniek, E.; Voswinckel, R.; Fink, L.; Scheed, A.; Ritter, C.; Dahal, B.K.; Vater, A.; et al. Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 2012, 186, 897–908. [Google Scholar] [CrossRef] [PubMed]
- Qiu, H.; He, Y.; Ouyang, F.; Jiang, P.; Guo, S.; Guo, Y. The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. J. Am. Heart Assoc. 2019, 8, e014201. [Google Scholar] [CrossRef]
- Van Uden, D.; Van Nimwegen, M.; Koudstaal, T.; Heukels, P.; Van Hulst, J.; Boomars, K.; Hendriks, R.; Kool, M. Alterations in circulating helper T-cells in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2019, 54, PA5051. [Google Scholar] [CrossRef]
- Heukels, P.; Corneth, O.B.J.; van Uden, D.; Hulst, J.A.C.V.; Toorn, L.M.V.D.; Bosch, A.E.V.D.; Wijsenbeek, M.S.; Boomars, K.A.; Kool, M.; Hendriks, R.W. Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension. Thorax 2021, 76, 1209–1218. [Google Scholar] [CrossRef]
- Maston, L.D.; Jones, D.T.; Giermakowska, W.; Howard, T.A.; Cannon, J.L.; Wang, W.; Wei, Y.; Xuan, W.; Resta, T.C.; Bosc, L.V.G. Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension. Am. J. Physiol. Cell. Mol. Physiol. 2017, 312, L609–L624. [Google Scholar] [CrossRef] [Green Version]
- Hautefort, A.; Girerd, B.; Montani, D.; Cohen-Kaminsky, S.; Price, L.; Lambrecht, B.N.; Humbert, M.; Perros, F. T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension. Chest 2015, 147, 1610–1620. [Google Scholar] [CrossRef] [PubMed]
- Ulrich, S.; Nicolls, M.R.; Taraseviciene, L.; Speich, R.; Voelkel, N. Increased Regulatory and Decreased CD8+ Cytotoxic T Cells in the Blood of Patients with Idiopathic Pulmonary Arterial Hypertension. Respiration 2007, 75, 272–280. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Austin, E.; Rock, M.; Mosse, C.; Vnencak-Jones, C.; Yoder, S.; Robbins, I.; Loyd, J.; Meyrick, B. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir. Med. 2010, 104, 454–462. [Google Scholar] [CrossRef] [Green Version]
- Sada, Y.; Dohi, Y.; Uga, S.; Higashi, A.; Kinoshita, H.; Kihara, Y. Non-suppressive regulatory T cell subset expansion in pulmonary arterial hypertension. Heart Vessel. 2015, 31, 1319–1326. [Google Scholar] [CrossRef]
- Montani, D.; Günther, S.; Dorfmüller, P.; Perros, F.; Girerd, B.; Garcia, G.; Jaïs, X.; Savale, L.; Artaud-Macari, E.; Price, L.C.; et al. Pulmonary arterial hypertension. Orphanet J. Rare Dis. 2013, 8, 97. [Google Scholar] [CrossRef] [Green Version]
- Zou, H.-X.; Qiu, B.-Q.; Lai, S.-Q.; Zhou, X.-L.; Gong, C.-W.; Wang, L.-J.; Yuan, M.-M.; He, A.-D.; Liu, J.-C.; Huang, H. Iron Metabolism and Idiopathic Pulmonary Arterial Hypertension: New Insights from Bioinformatic Analysis. BioMed Res. Int. 2021, 2021, 1–27. [Google Scholar] [CrossRef]
- Ars, C.; Thurion, P.; Delos, M.; Sibille, Y.; Pilette, C. Small airway obstruction in severe pulmonary arterial hypertension correlates with increased airway CD8+ T-cells and fractalkine expression. Eur. Respir. J. 2009, 34, 1494–1496. [Google Scholar] [CrossRef] [Green Version]
- Pioli, C.; Gatta, L.; Ubaldi, V.; Doria, G. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J. Immunol. 2000, 165, 5530–5536. [Google Scholar] [CrossRef] [Green Version]
- Kuiper, H.M.; Brouwer, M.; Linsley, P.S.; Van Lier, R.A. Activated T cells can induce high levels of CTLA-4 expression on B cells. J. Immunol. 1995, 155, 1776–1783. [Google Scholar]
- van Uden, D.; Koudstaal, T.; van Hulst, J.A.C.; Vink, M.; van Nimwegen, M.; Toorn, L.M.V.D.; Chandoesing, P.P.; Bosch, A.E.V.D.; Kool, M.; Hendriks, R.W.; et al. Peripheral Blood T Cells of Patients with IPAH Have a Reduced Cytokine-Producing Capacity. Int. J. Mol. Sci. 2022, 23, 6508. [Google Scholar] [CrossRef] [PubMed]
- Galiè, N.; Humbert, M.; Vachiery, J.; Gibbs, S.; Lang, I.; Torbicki, A.; Simmonneau, G.; Peacock, A.; VonkNoordegraaf, A.; Beghetti, M.; et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016, 37, 67–119. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Evaluation of the percentage of lymphocytes (B CD19+, T CD4+, T CD8+) with CTLA-4 antigen expression in a patient with idiopathic pulmonary arterial hypertension. The signal confirming the presence of receptors on cells was present on 2.83% of CD19+ B cells, 4.99% of CD4+ T cells, and 2.60% of CD8+ T cells.
Figure 1.
Evaluation of the percentage of lymphocytes (B CD19+, T CD4+, T CD8+) with CTLA-4 antigen expression in a patient with idiopathic pulmonary arterial hypertension. The signal confirming the presence of receptors on cells was present on 2.83% of CD19+ B cells, 4.99% of CD4+ T cells, and 2.60% of CD8+ T cells.
Figure 2.
Percentage of CD4+CTLA4+ T lymphocytes in CHD-PAH, CTD-PAH, CTEPH, iPAH patients and control subjects.
Figure 2.
Percentage of CD4+CTLA4+ T lymphocytes in CHD-PAH, CTD-PAH, CTEPH, iPAH patients and control subjects.
Figure 3.
Percentage of CD8+CTLA4+ T lymphocytes in CHD-PAH, CTD-PAH, CTEPH, iPAH patients and control subjects.
Figure 3.
Percentage of CD8+CTLA4+ T lymphocytes in CHD-PAH, CTD-PAH, CTEPH, iPAH patients and control subjects.
Figure 4.
Percentage of CD19+CTLA4+ B lymphocytes in CHD-PAH, CTD-PAH, CTEPH, iPAH patients and control subjects.
Figure 4.
Percentage of CD19+CTLA4+ B lymphocytes in CHD-PAH, CTD-PAH, CTEPH, iPAH patients and control subjects.
Figure 5.
Percentage of CD4+CTLA4+ T lymphocytes in iPAH patients taking into account the survival of patients with iPAH (p ≤ 0.01).
Figure 5.
Percentage of CD4+CTLA4+ T lymphocytes in iPAH patients taking into account the survival of patients with iPAH (p ≤ 0.01).
Figure 6.
Percentage of CD8+CTLA4+ T lymphocytes in iPAH patients taking into account the survival of patients with iPAH (p ≤ 0.001).
Figure 6.
Percentage of CD8+CTLA4+ T lymphocytes in iPAH patients taking into account the survival of patients with iPAH (p ≤ 0.001).
Figure 7.
T CD4+CTLA4+ cells [%] and New York Heart Association (NYHA) Functional Classification; Spearman’s rank correlation r = 0.7077, p < 0.001.
Figure 7.
T CD4+CTLA4+ cells [%] and New York Heart Association (NYHA) Functional Classification; Spearman’s rank correlation r = 0.7077, p < 0.001.
Figure 8.
B CD19+CTLA–4+ cells [%] and NT–proBNP concentration [pg/mL]; Spearman’s rank correlation r = 0.8498, p < 0.001.
Figure 8.
B CD19+CTLA–4+ cells [%] and NT–proBNP concentration [pg/mL]; Spearman’s rank correlation r = 0.8498, p < 0.001.
Table 1.
Evaluation of the percentage of CTLA-4 molecule in CHD-PAH, CTD-PAH, CTEPH and iPAH patients and controls.
Table 1.
Evaluation of the percentage of CTLA-4 molecule in CHD-PAH, CTD-PAH, CTEPH and iPAH patients and controls.
| Variable | Group | Median | Minimum | Maximum | Arithmetic Mean | SD | p |
|---|---|---|---|---|---|---|---|
| T-cells CD4+CTLA-4+ [%] | CHD-PAH | 9.42 | 0.11 | 24.84 | 10.17 | 6.03 | CHD-PAH vs. CTD-PAH (p ≤ 0.001), Control vs. CTD-PAH (p < 0.01), CHD-PAH vs. CTEPH (p < 0.01), CHD-PAH vs. iPAH (p < 0.01), Control vs. iPAH (p ≤ 0.001), CTD-PAH vs. iPAH (p ≤ 0.001), CTEPH vs. iPAH (p ≤ 0.001) |
| CTD-PAH | 2.04 | 0.53 | 2.4 | 1.8 | 0.6 | ||
| CTEPH | 3.91 | 2.57 | 5.4 | 3.98 | 1.02 | ||
| iPAH | 12.84 | 10.6 | 30.05 | 14.82 | 5.13 | ||
| control | 6.66 | 3.91 | 8.91 | 6.73 | 1.26 | ||
| T-cells CD8+CTLA-4+ [%] | CHD-PAH | 7.49 | 1.4 | 16.32 | 8.18 | 3.85 | CHD-PAH vs. control (p < 0.05), Control vs. iPAH (p ≤ 0.001) |
| CTD-PAH | 7.01 | 6.41 | 10.05 | 7.29 | 1.14 | ||
| CTEPH | 6.98 | 4.18 | 9.85 | 6.66 | 1.95 | ||
| iPAH | 8.33 | 4 | 25.11 | 10.58 | 6 | ||
| control | 5.46 | 1.36 | 8.54 | 5.19 | 1.87 | ||
| B-cells CD19+CTLA-4+ [%] | CHD-PAH | 3.72 | 0.59 | 11.37 | 4.88 | 2.91 | CHD-PAH vs. iPAH (p < 0.05), CTD-PAH vs. iPAH (p < 0.05), |
| CTD-PAH | 4.04 | 2.61 | 4.89 | 3.92 | 0.88 | ||
| CTEPH | 5.92 | 2.89 | 9.03 | 6.19 | 2.2 | ||
| iPAH | 8.01 | 2.69 | 18.28 | 8.34 | 4.8 | ||
| control | 5.68 | 2.48 | 8.47 | 5.35 | 1.92 |
Table 2.
Basic clinical and laboratory parameters characterizing patients with selected types of PAH and persons from the control group.
Table 2.
Basic clinical and laboratory parameters characterizing patients with selected types of PAH and persons from the control group.
| Parameter | Group | Median | Minimum | Maximum | Mean | SD | p |
|---|---|---|---|---|---|---|---|
| Age | CHD-PAH | 57.5 | 23 | 81 | 55.69 | 17.34 | CTEPH vs. CHD-PAH (p < 0.05), CTEPH vs. Control group (p < 0.05), CTEPH vs. CTD-PAH (p < 0.05), iPAH vs. CTEPH (p < 0.05), |
| CTD-PAH | 54 | 28 | 77 | 52.22 | 18.69 | ||
| CTEPH | 72.5 | 54 | 81 | 71.1 | 8.85 | ||
| iPAH | 62 | 23 | 81 | 56.52 | 17.23 | ||
| Control group | 56 | 39 | 77 | 58.05 | 11.12 | ||
| BMI | CHD-PAH | 24.91 | 19.5 | 38.15 | 25.54 | 4.18 | - |
| CTD-PAH | 22 | 20.32 | 27.98 | 23.79 | 2.96 | ||
| CTEPH | 23.67 | 20.44 | 35.04 | 24.74 | 4.18 | ||
| iPAH | 26 | 17.1 | 40.52 | 27.53 | 5.78 | ||
| Control group | - | - | - | - | - | ||
| 6MWT [m] | CHD-PAH | 378 | 50 | 578 | 323.15 | 149.64 | - |
| CTD-PAH | 420 | 80 | 577.5 | 382.17 | 149.99 | ||
| CTEPH | 358.5 | 190 | 561 | 356.1 | 110.94 | ||
| iPAH | 374 | 136 | 556 | 377.84 | 99.38 | ||
| Control group | - | - | - | - | - | ||
| Neutrophilscount [103/mm3] | CHD-PAH | 4.55 | 2.3 | 9.69 | 4.64 | 1.82 | - |
| CTD-PAH | 4.29 | 2.14 | 7.91 | 4.8 | 1.7 | ||
| CTEPH | 4.64 | 1.74 | 9.01 | 5.01 | 2.24 | ||
| iPAH | 5.11 | 2.08 | 8.43 | 5.16 | 1.64 | ||
| Control group | 3.94 | 2.71 | 6.03 | 4.32 | 1.03 | ||
| Lymphocytes count [103/mm3] | CHD-PAH | 1.68 | 1.1 | 2.77 | 1.72 | 0.46 | Control group vs. CHD-PAH (p ≤ 0.001), CTD-PAH vs. CHD-PAH (p ≤ 0.001), iPAH vs. CHD-PAH (p < 0.05), iPAH vs. CTD-PAH (p < 0.05) |
| CTD-PAH | 2.6 | 1.67 | 3.04 | 2.47 | 0.4 | ||
| CTEPH | 2.42 | 1.3 | 3.83 | 2.51 | 0.96 | ||
| iPAH | 2.01 | 1.2 | 3.14 | 2.15 | 0.56 | ||
| Control group | 2.54 | 1.53 | 3.07 | 2.44 | 0.45 | ||
| Hemoglobin concentration [g/dL] | CHD-PAH | 15.1 | 7.4 | 22.1 | 15.4 | 4.38 | - |
| CTD-PAH | 13.5 | 11.3 | 19.4 | 13.76 | 2.42 | ||
| CTEPH | 13.75 | 8.5 | 16.7 | 13.24 | 2.65 | ||
| iPAH | 13.6 | 9.5 | 18.5 | 13.69 | 2.04 | ||
| Control group | 14.35 | 12.5 | 15.6 | 14.31 | 0.86 | ||
| Platelets count [mm3] | CHD-PAH | 156,500 | 62,000 | 299,000 | 164,115 | 64,380 | Control group vs. CHD-PAH (p ≤ 0.001), CTD-PAH vs. CHD-PAH (p < 0.05), iPAH vs. CHD-PAH (p < 0.05), CTD-PAH vs. Control group (p ≤ 0.001), CTEPH vs. Control group (p < 0.01), iPAH vs. Control group (p < 0.01), CTEPH vs. CTD-PAH (p < 0.05), iPAH vs. CTD-PAH (p ≤ 0.001) |
| CTD-PAH | 114,000 | 55,000 | 309,000 | 147,889 | 92,369 | ||
| CTEPH | 182,500 | 93,000 | 348,000 | 189,000 | 73,138 | ||
| iPAH | 213,000 | 78,000 | 474,000 | 213,800 | 80,647 | ||
| Control group | 262,500 | 186,000 | 344,000 | 263,950 | 52,744 | ||
| AspAT [U/L] | CHD-PAH | 20 | 12 | 68 | 25.46 | 13.95 | - |
| CTD-PAH | 32 | 17 | 38 | 27.67 | 7.79 | ||
| CTEPH | 27 | 19 | 127 | 36.4 | 32.22 | ||
| iPAH | 22 | 10 | 49 | 23.12 | 9.18 | ||
| Control group | 22.5 | 13 | 34 | 22.6 | 6.1 | ||
| ALAT [U/L] | CHD-PAH | 16 | 26 | 22 | 22 | 16.87 | Control group vs. CHD-PAH (p < 0.05), CTEPH vs. CHD-PAH (p < 0.01), CTEPH vs. CTD-PAH (p < 0.05), iPAH vs. CTEPH (p < 0.05) |
| CTD-PAH | 18 | 9 | 25.78 | 25.78 | 21.72 | ||
| CTEPH | 22.5 | 10 | 29.8 | 29.8 | 22.05 | ||
| iPAH | 18 | 25 | 20.04 | 20.04 | 10.41 | ||
| Control group | 18.5 | 20 | 19.75 | 19.75 | 7.49 | ||
| T CD3+ lymphocytes [%] | CHD-PAH | 71.3 | 60.29 | 80.9 | 70.68 | 6.31 | - |
| CTD-PAH | 70.53 | 57.31 | 80.45 | 70.29 | 6.85 | ||
| CTEPH | 69.8 | 63.1 | 81.62 | 71.07 | 6.3 | ||
| iPAH | 70.82 | 59.21 | 89.16 | 71.11 | 6.84 | ||
| Control group | 68.08 | 60.63 | 74.49 | 68.26 | 3.84 | ||
| B CD19+ lymphocytes [%] | CHD-PAH | 9.36 | 2.46 | 26.25 | 9.76 | 4.89 | |
| CTD-PAH | 9.05 | 2.79 | 21.99 | 10.18 | 6.29 | ||
| CTEPH | 11.25 | 5.36 | 16.91 | 11.01 | 4.14 | ||
| iPAH | 11.9 | 3.5 | 20.67 | 11.36 | 4.97 | ||
| Control group | 11.39 | 6.04 | 16.9 | 11.25 | 2.5 | ||
| NK cells (CD3-/CD16+CD56+) [%] | CHD-PAH | 22.37 | 6.63 | 37.5 | 20.88 | 7.97 | Control group vs. CHD-PAH (p < 0.05). CTD-PAH vs. CHD-PAH (p ≤ 0.001). CTEPH vs. CHD-PAH (p ≤ 0.001). iPAH vs. CHD-PAH (p ≤ 0.001). CTD-PAH vs. Control group (p ≤ 0.001). CTEPH vs. Control group (p < 0.05). iPAH vs. Control group (p ≤ 0.001) |
| CTD-PAH | 10.9 | 2.34 | 19.77 | 10.82 | 5.76 | ||
| CTEPH | 8.93 | 4.32 | 17.41 | 9.65 | 4.6 | ||
| iPAH | 11.23 | 3.99 | 20.43 | 11.1 | 4.22 | ||
| Control group | 14.43 | 12.16 | 19.34 | 15.35 | 2.25 | ||
| NKT-like cells CD3+CD16+CD56+ [%] | CHD-PAH | 1.58 | 0.24 | 8.47 | 2.62 | 2.31 | CHD-PAH vs. iPAH (p < 0.01) |
| CTD-PAH | 1.04 | 0.21 | 8.2 | 2.97 | 3.08 | ||
| CTEPH | 3.17 | 0.77 | 11.26 | 4.1 | 3.68 | ||
| iPAH | 5.23 | 0.67 | 10.94 | 5.26 | 2.67 | ||
| Control group | 3.27 | 1.15 | 4.92 | 3.02 | 1.02 | ||
| T CD4+/CD3+ lymphocytes [%] | CHD-PAH | 42.16 | 21.58 | 57.43 | 41.25 | 10 | CTD-PAH vs. Control group (p < 0.01). CTEPH vs. CTD-PAH (p < 0.01) |
| CTD-PAH | 35.54 | 28.43 | 59.88 | 39.84 | 10.22 | ||
| CTEPH | 45.37 | 39.14 | 51.33 | 45.42 | 4.47 | ||
| iPAH | 36.91 | 19.73 | 62.92 | 38.68 | 13.42 | ||
| Control group | 44.16 | 40.71 | 48.84 | 44.46 | 2.5 | ||
| T CD8+/CD3+ lymphocytes [%] | CHD-PAH | 27.21 | 12.78 | 47.16 | 26.94 | 8.2 | Control group vs. CHD-PAH (p ≤ 0.001). CTEPH vs. Control group (p < 0.01). iPAH vs. Control group (p ≤ 0.001) |
| CTD-PAH | 30.62 | 10.18 | 39.87 | 28 | 10.82 | ||
| CTEPH | 20.29 | 11.17 | 36.94 | 23.02 | 7.67 | ||
| iPAH | 28.3 | 9.19 | 59.29 | 29.46 | 14.17 | ||
| Control group | 34.73 | 29.33 | 39.6 | 34.36 | 3.29 | ||
| T CD4+: T CD8+ lymphocytes ratio | CHD-PAH | 1.62 | 0.46 | 4.49 | 1.78 | 0.95 | Control group vs. CTEPH (p < 0.05), CTD-PAH vs. CTEPH (p < 0.05) |
| CTD-PAH | 1.31 | 0.87 | 4.86 | 1.84 | 1.38 | ||
| CTEPH | 2.09 | 1.09 | 4.5 | 2.24 | 0.97 | ||
| iPAH | 1.25 | 0.34 | 6.85 | 1.95 | 1.78 | ||
| Control group | 1.29 | 1.03 | 1.57 | 1.31 | 0.16 | ||
| T regulatory cells [%] | CHD-PAH | 7.43 | 4.67 | 15.59 | 8.43 | 2.87 | CHD-PAH vs. CTEPH (p < 0.01), Control group vs. CTEPH (p < 0.05), CTD-PAH vs. CTEPH (p < 0.05), CHD-PAH vs. iPAH (p < 0.01), Control group vs. iPAH (p ≤ 0.001), CTD-PAH vs. iPAH (p < 0.05), TEPH vs. iPAH (p ≤ 0.001) |
| CTD-PAH | 7.25 | 4.73 | 11.59 | 8.11 | 2.39 | ||
| CTEPH | 4.13 | 1.79 | 10.33 | 4.65 | 2.55 | ||
| iPAH | 11.21 | 5.94 | 23.81 | 11.98 | 3.97 | ||
| Control group | 7.37 | 3.15 | 10.15 | 7.1 | 1.94 | ||
| NT-proBNP [pg/mL] | CHD-PAH | 836 | 106.8 | 9350 | 1597.66 | 1930.48 | - |
| CTD-PAH | 1279 | 429 | 4015 | 1530 | 1384.07 | ||
| CTEPH | 1756.5 | 53 | 5991 | 2071.52 | 1617.33 | ||
| iPAH | 1546 | 210 | 10,144 | 1940.22 | 2072.29 | ||
| Control group | - | - | - | - | - |
6MWT: 6-min walk test; ALAT: alanine transaminase; AspAT: aspartate transaminase; BMI: body mass index; CHD-PAH: pulmonary arterial hypertension associated with congenital heart disease; CTD-PAH: pulmonary arterial hypertension associated with connective tissue disease; CTEPH: chronic thromboembolic pulmonary hypertension; iPAH: idiopathic pulmonary arterial hypertension; NK: natural killer; SD: standard deviation.
Table 3.
Basic hemodynamic parameters assessed during cardiac catheterization and echocardiography in patients with CHD-PAH, CTD-PAH, CTEPH and iPAH.
Table 3.
Basic hemodynamic parameters assessed during cardiac catheterization and echocardiography in patients with CHD-PAH, CTD-PAH, CTEPH and iPAH.
| Parameter | Group | Median | Minimum | Maximum | Mean | SD | p |
|---|---|---|---|---|---|---|---|
| Pulmonary vascular resistance (PVR) [dyne/s/cm−5 | CHD-PAH | 838.62 | 134 | 2803 | 1066.32 | 696.02 | CHD-PAH vs. CTD-PAH (p ≤ 0.001). CTD-PAH vs. CTEPH (p < 0.05). CTD-PAH vs. iPAH (p < 0.05) |
| CTD-PAH | 355 | 139 | 1292 | 424.53 | 369.55 | ||
| CTEPH | 715.5 | 305.51 | 1125.8 | 720.4 | 234.12 | ||
| iPAH | 651 | 158 | 1599 | 697.6 | 314.62 | ||
| Control group | - | - | - | - | - | ||
| Cardiac index (CI) [L/min/m2] | CHD-PAH | 2.27 | 1.65 | 7.32 | 2.52 | 1.08 | CTEPH vs. CHD-PAH (p < 0.05). CTEPH vs. CTD-PAH (p < 0.05). iPAH vs. CTEPH (p < 0.01) |
| CTD-PAH | 3.21 | 1.83 | 4.67 | 3.16 | 0.83 | ||
| CTEPH | 2.05 | 1.75 | 5.8 | 2.53 | 1.25 | ||
| iPAH | 2.6 | 1.43 | 3.75 | 2.54 | 0.65 | ||
| Control group | - | - | - | - | - | ||
| Cardiac output (CO) [L/min] | CHD-PAH | 3.84 | 2.29 | 13.9 | 4.2 | 2.11 | CTD-PAH vs. CHD-PAH (p ≤ 0.001). iPAH vs. CHD-PAH (p < 0.01). CTEPH vs. CTD-PAH (p < 0.01). iPAH vs. CTEPH (p < 0.05) |
| CTD-PAH | 5.75 | 3.02 | 8.47 | 5.37 | 1.57 | ||
| CTEPH | 3.56 | 2.48 | 9.51 | 4.19 | 2.17 | ||
| iPAH | 4.46 | 2.11 | 6.42 | 4.64 | 1.15 | ||
| Control group | - | - | - | - | - | ||
| Mean right atrial pressure (mRAP) [mmHg] | CHD-PAH | 8 | 1 | 16 | 7.88 | 3.25 | - |
| CTD-PAH | 8 | 3 | 15 | 8.56 | 4.03 | ||
| CTEPH | 9 | 3 | 18 | 9.5 | 5.02 | ||
| iPAH | 9 | 2 | 23 | 8.8 | 5.69 | ||
| Control group | - | - | - | - | - | ||
| Mean pulmonary artery pressure (mPAP) [mmHg] | CHD-PAH | 48.5 | 26 | 106 | 53.61 | 22.76 | CHD-PAH vs. CTD-PAH (p < 0.01). CTD-PAH vs. CTEPH (p < 0.05). CTD-PAH vs. iPAH (p < 0.05) |
| CTD-PAH | 34 | 25 | 68 | 35.3 | 13.25 | ||
| CTEPH | 46 | 25.6 | 56 | 45.66 | 8.75 | ||
| iPAH | 48 | 25 | 66 | 45.56 | 12.03 | ||
| Control group | - | - | - | - | - | ||
| Mean pulmonary artery pressure by echocardiography (PASP) [mmHg] | CHD-PAH | 76.5 | 41 | 150 | 82.15 | 29.02 | CTD-PAH vs. CHD-PAH (p < 0.01). CTEPH vs. CTD-PAH (p < 0.05). iPAH vs. CTD-PAH (p < 0.05) |
| CTD-PAH | 57 | 35 | 110 | 58.22 | 21.68 | ||
| CTEPH | 78.5 | 39 | 110 | 80.4 | 21.57 | ||
| iPAH | 77 | 37 | 105 | 72.2 | 18.92 | ||
| Control group | - | - | - | - | - | ||
| Mean pressure in the right ventricle on echocardiography [mmHg] | CHD-PAH | 72 | 40 | 150 | 81.19 | 29.69 | CHD-PAH vs. CTD-PAH (p < 0.05). CTD-PAH vs. CTEPH (p < 0.05). |
| CTD-PAH | 56 | 36 | 115 | 58.67 | 24.07 | ||
| CTEPH | 76.5 | 50 | 110 | 79.7 | 18.54 | ||
| iPAH | 76 | 42 | 96 | 68.84 | 17.66 | ||
| Control group | - | - | - | - | - |
CHD-PAH: pulmonary arterial hypertension associated with congenital heart disease; CTD-PAH: pulmonary arterial hypertension associated with connective tissue disease; CTEPH: chronic thromboembolic pulmonary hypertension; iPAH: idiopathic pulmonary arterial hypertension; SD: standard deviation.
Table 4.
List of antibodies used to assess lymphocyte immunophenotype.
| Structure | Antibody | Fluorochrome |
|---|---|---|
| T-cells | anty–CD4 | FITC |
| T-cells | anty–CD8 | FITC |
| B-cells | anty–CD19 | FITC |
| CTLA-4 | anty–CTLA-4 | PE-Cy5 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Tomaszewski, M.; Małkowska, P.; Sierawska, O.; Hrynkiewicz, R.; Mroczek, E.; Darocha, S.; Hymos, A.; Błaszczak, P.; Grywalska, E.; Niedźwiedzka-Rystwej, P. CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension. Int. J. Mol. Sci. 2022, 23, 15910. https://doi.org/10.3390/ijms232415910
AMA Style
Tomaszewski M, Małkowska P, Sierawska O, Hrynkiewicz R, Mroczek E, Darocha S, Hymos A, Błaszczak P, Grywalska E, Niedźwiedzka-Rystwej P. CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension. International Journal of Molecular Sciences. 2022; 23(24):15910. https://doi.org/10.3390/ijms232415910
Chicago/Turabian StyleTomaszewski, Michał, Paulina Małkowska, Olga Sierawska, Rafał Hrynkiewicz, Ewa Mroczek, Szymon Darocha, Anna Hymos, Piotr Błaszczak, Ewelina Grywalska, and Paulina Niedźwiedzka-Rystwej. 2022. "CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension" International Journal of Molecular Sciences 23, no. 24: 15910. https://doi.org/10.3390/ijms232415910
APA StyleTomaszewski, M., Małkowska, P., Sierawska, O., Hrynkiewicz, R., Mroczek, E., Darocha, S., Hymos, A., Błaszczak, P., Grywalska, E., & Niedźwiedzka-Rystwej, P. (2022). CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension. International Journal of Molecular Sciences, 23(24), 15910. https://doi.org/10.3390/ijms232415910
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
